Cargando…

Stereotactic body radiation therapy use for high risk prostate cancer in the United States

Detalles Bibliográficos
Autores principales: Patel, Sagar A., Switchenko, Jeffrey M., Kishan, Amar U., Jani, Ashesh B., Royce, Trevor J., Fischer-Valuck, Benjamin W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116349/
https://www.ncbi.nlm.nih.gov/pubmed/33188271
http://dx.doi.org/10.1038/s41391-020-00300-5
_version_ 1783691383586947072
author Patel, Sagar A.
Switchenko, Jeffrey M.
Kishan, Amar U.
Jani, Ashesh B.
Royce, Trevor J.
Fischer-Valuck, Benjamin W.
author_facet Patel, Sagar A.
Switchenko, Jeffrey M.
Kishan, Amar U.
Jani, Ashesh B.
Royce, Trevor J.
Fischer-Valuck, Benjamin W.
author_sort Patel, Sagar A.
collection PubMed
description
format Online
Article
Text
id pubmed-8116349
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-81163492021-06-01 Stereotactic body radiation therapy use for high risk prostate cancer in the United States Patel, Sagar A. Switchenko, Jeffrey M. Kishan, Amar U. Jani, Ashesh B. Royce, Trevor J. Fischer-Valuck, Benjamin W. Prostate Cancer Prostatic Dis Correspondence Nature Publishing Group UK 2020-11-13 2021 /pmc/articles/PMC8116349/ /pubmed/33188271 http://dx.doi.org/10.1038/s41391-020-00300-5 Text en © The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Correspondence
Patel, Sagar A.
Switchenko, Jeffrey M.
Kishan, Amar U.
Jani, Ashesh B.
Royce, Trevor J.
Fischer-Valuck, Benjamin W.
Stereotactic body radiation therapy use for high risk prostate cancer in the United States
title Stereotactic body radiation therapy use for high risk prostate cancer in the United States
title_full Stereotactic body radiation therapy use for high risk prostate cancer in the United States
title_fullStr Stereotactic body radiation therapy use for high risk prostate cancer in the United States
title_full_unstemmed Stereotactic body radiation therapy use for high risk prostate cancer in the United States
title_short Stereotactic body radiation therapy use for high risk prostate cancer in the United States
title_sort stereotactic body radiation therapy use for high risk prostate cancer in the united states
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116349/
https://www.ncbi.nlm.nih.gov/pubmed/33188271
http://dx.doi.org/10.1038/s41391-020-00300-5
work_keys_str_mv AT patelsagara stereotacticbodyradiationtherapyuseforhighriskprostatecancerintheunitedstates
AT switchenkojeffreym stereotacticbodyradiationtherapyuseforhighriskprostatecancerintheunitedstates
AT kishanamaru stereotacticbodyradiationtherapyuseforhighriskprostatecancerintheunitedstates
AT janiasheshb stereotacticbodyradiationtherapyuseforhighriskprostatecancerintheunitedstates
AT roycetrevorj stereotacticbodyradiationtherapyuseforhighriskprostatecancerintheunitedstates
AT fischervaluckbenjaminw stereotacticbodyradiationtherapyuseforhighriskprostatecancerintheunitedstates